RxDoctor Payments DataLook up a doctor →

Damian Sorce, MD

Urology · Parker, CONPI 1952457632

Payments from drug & device makers

$223,794in general payments, 2019–2025

Across 533 payments — averaging $419.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$90K
  • Johnson & Johnson$48K
  • Dendreon Pharmaceuticals LLC$31K
  • Myovant Sciences Inc.$23K
  • Teleflex LLC$7K
  • Pfizer$5K
  • plus $19K from 37 others

What the payments were for

  • Consulting fees$15,5947%
  • Speaking & faculty fees$169,65676%
  • Travel & lodging$21,69310%
  • Food & beverage$16,4107%
  • Education$4420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$223,794 in reported general payments places this provider in the 95th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$469,077
Medicare patients
507
Services billed
3,715

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide195$2,670,753
ErleadaApalutamide97$1,426,535
OrgovyxRelugolix327$891,714
NubeqaDarolutamide20$301,592
Abiraterone Acetate54$96,850
MyrbetriqMirabegron39$48,261
GemtesaVibegron46$43,956
Finasteride407$5,174
Testosterone13$4,640
Tamsulosin Hcl404$4,612
Potassium Citrate ErPotassium Citrate26$2,779
Dutasteride41$2,012
Testosterone Cypionate52$1,942
Oxybutynin Chloride ErOxybutynin Chloride42$1,245
Oxybutynin Chloride29$930

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$826$2,719,014234 claims
Johnson & JohnsonErleada$48,379$1,426,53597 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$89,808$935,670373 claims
BayerNubeqa$1,285$301,59220 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$3,653$96,85054 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 225 urology providers in Colorado.

Other urology in Parker

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →